A Study to Assess Anktiva in Patients With Long Covid-19.
Trial details
- Registry ID
- NCT07108036
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess Anktiva in Patients With Long Covid-19.NCT07108036 | IBRX | Phase 2 | Recruiting | 2026-10Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |